EDGAR·FLOW

Cue Biopharma, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Cue Biopharma reported Q3 2026 net loss of $50.0M (vs. $7.4M in Q3 2025) driven by $17.0M R&D and $29.8M G&A expenses, largely non-cash stock compensation. CUE-221 Phase 2 CSU trial showed dose-responsive hive resolution (78% complete response at 4 mg/kg vs. 0% placebo in high-IgE subgroup); CUE-401 first-in-human Phase 1 dosing initiated. Cash position: $57.9M as of September 30, 2026; ImmunoScape payment increased to $5.5M total (Nov 2026 amendment).
Why this rating

Clinical validation of lead asset CUE-221 and autoimmune pipeline entry are strategically meaningful; however, massive burn ($153.8M nine-month operating loss) and modest cash runway (≈3–4 quarters at current burn) create material financing risk for $52M market-cap company.

Tradability signal
NO TRADE

No trade: the filing reads positive but the market is selling it (-10.6% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$14.10 ▲ 4.64%
at our read · unknown
$13.47
+10 min · unknown
$11.80 ▼ 12.43%
+30 min · unknown
$9.01 ▼ 33.14%
+1 hr · unknown
$9.12 ▼ 32.29%
+4 hrs · unknown
$5.54 ▼ 58.89%

The stock had already moved -4.43% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ CUE · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.